METHYLGLYOXAL BIS(CYCLOPENTYLAMIDINOHYDRAZONE) (MGBCP) - ANTITUMOR EFFECT AGAINST HUMAN OSTEOSARCOMA CELLS AND COMBINED EFFECT WITH METHOTREXATE, ADRIAMYCIN AND 4-HYDROPEROXYIFOSFAMIDE

Authors
SONODA J HIBASAMI H YAMADA H FUJINAMI S NAKASHIMA K OGIHARA Y
Citation
J. Sonoda et al., METHYLGLYOXAL BIS(CYCLOPENTYLAMIDINOHYDRAZONE) (MGBCP) - ANTITUMOR EFFECT AGAINST HUMAN OSTEOSARCOMA CELLS AND COMBINED EFFECT WITH METHOTREXATE, ADRIAMYCIN AND 4-HYDROPEROXYIFOSFAMIDE, Anticancer research, 15(3), 1995, pp. 907-909
Citations number
10
Categorie Soggetti
Oncology
Journal title
Anticancer research → ACNP
ISSN journal
02507005
Volume
15
Issue
3
Year of publication
1995
Pages
907 - 909
Database
ISI
SICI code
0250-7005(1995)15:3<907:MB(-AE>2.0.ZU;2-V
Abstract
The antitumor effect of a polyamine biosynthetic pathway inhibitor met hylglyoxal bis(cyclopentylamidinohydrazone) (MGBCP) on human osteosarc oma cell lines such as KHOS-240S, MG-63 and G-292 cells, and its effec t in combination with anticancer drugs such as methotrexate (MTX), adr iamycin (ADM) and 4-hydroperoxyfosfamide (HIFO) have been investigated . The growth of these cultured osteosarcoma cells was inhibited by MGB CP in a dose-dependent manner. Spermidine and spermine levels were dos e-dependently depressed in these MGBCP-treated osteosarcoma cells. The antitumor effect of MGBCP was additively potentiated by combined trea tment with MTX, ADM and HIFO, respectively.